Five British ale yeast strains were subjected to flavour profiling under brewery fermentation conditions in which all other brewing parameters were kept constant. Significant variation was observed in the timing and quantity of flavour-related chemicals produced. Genetic tests showed no evidence of hybrid origins in any of the strains, including one strain previously reported as a possible hybrid of Saccharomyces cerevisiae and S. bayanus. Variation maintained in historical S. cerevisiae ale yeast collections is highlighted as a potential source of novelty in innovative strain improvement for bioflavour production.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383656 | PMC |
| http://dx.doi.org/10.1002/yea.3052 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A bulk-surface mechanobiochemical modelling approach for single cell migration in two-space dimensions.
J Theor Biol
December 2024
University of British Columbia, Department of Mathematics, 1984 Mathematics Road, Vancouver, V6T 1Z2, British Columbia, Canada; University of Pretoria, Department of Mathematics, Pretoria, South Africa; University of Johannesburg, Department of Mathematics, Johannesburg, South Africa; University of Zimbabwe, Department of Mathematics and Computational Science, Mt Pleasant, Harare, Zimbabwe. Electronic address:
In this work, we present a mechanobiochemical model for two-dimensional cell migration which couples mechanical properties of the cell cytosol with biochemical processes taking place near or on the cell plasma membrane. The modelling approach is based on a recently developed mathematical formalism of evolving bulk-surface partial differential equations of reaction-diffusion type. We solve these equations using finite element methods within a moving-mesh framework derived from the weak formulation of the evolving bulk-surface PDEs.
View Article and Find Full Text PDFEleven neurology-related proteins measured in serum are positively correlated to the severity of diabetic neuropathy.
Sci Rep
July 2024
Pain and Rehabilitation Center, and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
About 20% of patients with diabetes suffer from chronic pain with neuropathic characteristics. We investigated the multivariate associations between 92 neurology-related proteins measured in serum from 190 patients with painful and painless diabetic neuropathy. Participants were recruited from the Pain in Neuropathy Study, an observational cross-sectional multicentre study in which participants underwent deep phenotyping.
View Article and Find Full Text PDFEmpagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Lancet Diabetes Endocrinol
December 2023
Background: Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19.
Methods: In the randomised, controlled, open-label RECOVERY trial, several possible treatments are compared with usual care in patients hospitalised with COVID-19.
Structural journey of an insecticidal protein against western corn rootworm.
Nat Commun
July 2023
Institute of Structural and Molecular Biology, Birkbeck, University of London, Malet St, London, WC1E 7HX, UK.
The broad adoption of transgenic crops has revolutionized agriculture. However, resistance to insecticidal proteins by agricultural pests poses a continuous challenge to maintaining crop productivity and new proteins are urgently needed to replace those utilized for existing transgenic traits. We identified an insecticidal membrane attack complex/perforin (MACPF) protein, Mpf2Ba1, with strong activity against the devastating coleopteran pest western corn rootworm (WCR) and a novel site of action.
View Article and Find Full Text PDFArticle Synopsis
- A study evaluated the effects of a higher dose of corticosteroids on COVID-19 patients who needed oxygen or ventilatory support, building on previous findings that low-dose corticosteroids reduced mortality in similar patients.
- The research was part of the RECOVERY trial, which randomly assigned patients to receive either higher dose corticosteroids or usual care with a lower dose, measuring 28-day mortality rates as the primary outcome.
- From May 2021 to May 2022, 1,272 patients were included, with notable participation from Asia and the UK; results showed that nearly all of the patients who received usual care also received some form of low-dose corticosteroids.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!